Search Results | Clinicalinfo

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Search Results 2401 – 2420 of 3231

Tratamiento como Prevención (TasP)

https://clinicalinfo.hiv.gov/glossary/tratamiento-como-prevencion-tasp

https://clinicalinfo.hiv.gov/contactenos

https://clinicalinfo.hiv.gov/contactenos

Coccidioidomycosis

https://clinicalinfo.hiv.gov/node/9160

Talaromycosis (Formerly Penicilliosis)

https://clinicalinfo.hiv.gov/node/9161

Human Papillomavirus Disease

https://clinicalinfo.hiv.gov/node/9164

Prepregnancy Counseling and Care

https://clinicalinfo.hiv.gov/node/9165

Reproductive Options When One or Both Partners Have HIV

https://clinicalinfo.hiv.gov/node/9166

Appendix B: Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy

https://clinicalinfo.hiv.gov/node/9167

Non-Nucleoside Reverse Transcriptase Inhibitors

https://clinicalinfo.hiv.gov/node/9168

https://clinicalinfo.hiv.gov/node/9169

Table 4. Significant Pharmacokinetic Interactions Between Drugs Used to Treat or Prevent Opportunistic Infections

https://clinicalinfo.hiv.gov/node/9170

Guidelines Panel Members

https://clinicalinfo.hiv.gov/node/9171

https://clinicalinfo.hiv.gov/node/9172

Amprenavir (Agenerase, APV)

https://clinicalinfo.hiv.gov/node/9173

Cytomegalovirus Disease

https://clinicalinfo.hiv.gov/node/9174

Limitations to Treatment Safety and Efficacy

https://clinicalinfo.hiv.gov/node/9175

Adherence to the Continuum of Care

https://clinicalinfo.hiv.gov/node/9176

Considerations for Antiretroviral Use in People With Coinfections

https://clinicalinfo.hiv.gov/node/9178

Tuberculosis/HIV Coinfection

https://clinicalinfo.hiv.gov/node/9179